Rubella Diagnostic Testing Market Forecast: How Big Will It Be by 2030?
Uncover key drivers, emerging technologies, and competitive movements shaping the rubella diagnostic testing market from 2026–2035 with trusted insights from The Business Research Company
How is the Rubella Diagnostic Testing Market size predicted to change over the forecast window of 2026–2035?
The rubella diagnostic testing market has experienced robust expansion in recent years. Its size is projected to increase from $1.39 billion in 2025 to $1.48 billion in 2026, indicating a compound annual growth rate (CAGR) of 6.5%. Historically, this growth can be attributed to the expansion of routine viral screening programs, increased awareness of congenital rubella syndrome, the availability of serological testing kits, the growth in diagnostic laboratory networks, and the adoption of immunoassay technologies.
The rubella diagnostic testing market size is projected to experience substantial expansion in the coming years, anticipated to reach $1.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.4%. This projected growth is driven by factors such as increased investments in sophisticated diagnostic platforms, a heightened emphasis on maternal health screening, the expansion of automated laboratory testing, the increasing uptake of point-of-care diagnostics, and the reinforcement of infectious disease surveillance systems. Key trends anticipated during this period encompass the growing adoption of molecular diagnostic techniques, an increase in PCR-based rubella testing, rising demand for prenatal screening, the broadening application of high-sensitivity immunoassays, and a greater focus on detecting diseases at an early stage.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19177&type=smp
Which Drivers Are Contributing To The Expansion Of The Rubella Diagnostic Testing Market?
The increasing prevalence of viral infections is anticipated to stimulate the expansion of the rubella diagnostic testing market in the future. Viral infections are illnesses caused by viruses, which are microscopic infectious agents only able to replicate within the living cells of an organism. This rise in viral infection cases stems from increased global travel, which facilitates the cross-border spread of viruses, and climate change, which alters vector habitats and expands the range of disease-carrying organisms. Rubella diagnostic testing aids in the early identification and management of rubella infections, thereby preventing complications, particularly for pregnant women, and assisting in outbreak containment to lessen virus transmission. For instance, in December 2023, data from the National Health Service, a UK-based government department, showed that daily hospital admissions for flu averaged 234, indicating a 53% increase from the previous week, while hospital cases of norovirus ascended by 15% to an average of 406 daily, reflecting a 28% increase from the same week last year. Consequently, the escalating instances of viral infections are propelling the growth of the rubella diagnostic testing market.
What Segment Classifications Make Up The Rubella Diagnostic Testing Market?
The rubella diagnostic testing market covered in this report is segmented –
1) By Diagnostic Technique: Latex Agglutination, Enzyme Immunoassay (EIA), Radioimmunoassay (Ria), Fluorescent Immunoassay (FIA), Other Diagnostic Techniques
2) By Age Group: Neonates, Teenagers, Adults
3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Public Health Laboratories, Other End Users
Subsegments:
1) By Latex Agglutination: Qualitative Latex Agglutination Tests, Quantitative Latex Agglutination Tests, Rapid Latex Agglutination Kits
2) By Enzyme Immunoassay (EIA): Direct EIA, Indirect EIA, Sandwich EIA, Competitive EIA
3) By Radioimmunoassay (RIA): Standard RIA, Modified RIA, Single-Antibody RIA
4) By Fluorescent Immunoassay (FIA): Direct FIA, Indirect FIA, Sandwich FIA
5) By Other Diagnostic Techniques: Polymerase Chain Reaction (PCR), Nucleic Acid Amplification Tests (NAAT), Microplate-Based Assays, Western Blotting
Which Trends Are Influencing The Performance And Direction Of The Rubella Diagnostic Testing Market?
Key companies operating within the rubella diagnostic testing market are concentrating on developing advanced solutions, such as a rubella virus vaccine, to enhance diagnostic precision and improve preventive measures. The rubella virus vaccine offers immunity against rubella, frequently given as part of the MMR or MMRV combination vaccines to prevent the disease and related complications. For example, in March 2023, Merck & Co., Inc., a pharmaceutical company based in the US, received FDA approval for the intramuscular (IM) administration of Merck’s M-M-R II vaccine, which is vital for protection against rubella, as well as measles and mumps. This approval allows healthcare providers to administer the rubella vaccine via the IM route, aligning its delivery with other routinely recommended pediatric vaccines. Rubella vaccination is crucial for preventing outbreaks and safeguarding against the severe complications the virus can cause, particularly in pregnant women.
Which Major Firms Are Strengthening Their Position In The Rubella Diagnostic Testing Market?
Major companies operating in the rubella diagnostic testing market are Cardinal Health Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, bioMérieux S.A., Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc., DiaSorin S.p.A., Meridian Bioscience Inc., Fortress Diagnostics Ltd., Mylab Discovery Solutions Pvt. Ltd., MP Biomedicals LLC, CTK Biotech Inc., ZEUS Scientific Inc., Creative Diagnostics, Arlington Scientific Inc., AccuBioTech Co. Ltd., Intec Products Inc., Vitrosens Biotechnology Ltd., Sprint Diagnostics Pvt. Ltd., InDevR Inc., Atlas Medical GmbH
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/rubella-diagnostic-testing-global-market-report
Which Region Is Anticipated To See The Fastest Growth In The Rubella Diagnostic Testing Market?
North America was the largest region in the rubella diagnostic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rubella diagnostic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Rubella Diagnostic Testing Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=19177&type=smp
Browse Through More Reports Similar to the Global Rubella Diagnostic Testing Market 2026, By The Business Research Company
Hospital Acquired Infections Testing Kits Market Report 2026
Gastrointestinal Pathogen Testing Market Report 2026
Clinical Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
